Press release for testing purposes
Page authored 19 February 2013, London UK
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed lobortis interdum mattis. Cras cursus tincidunt imperdiet. Fusce sed neque mauris. Curabitur sed sapien vel risus congue accumsan. Donec at est urna, at mollis lectus. Aenean auctor arcu at purus tristique ac suscipit eros sollicitudin. Duis ut vestibulum lectus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas et elit sit amet leo sodales porta at commodo odio. Sed ligula ante, consequat at pretium nec, pharetra ut diam. Vivamus lobortis mattis rutrum. Cras semper justo ac risus iaculis mollis.
Etiam consectetur posuere urna, vitae viverra sem lobortis quis. Phasellus elementum, felis sed elementum rhoncus, ipsum augue euismod quam, eu ultrices nisl tortor et tellus. Phasellus turpis arcu, fermentum posuere luctus quis, cursus vitae neque. Maecenas posuere mauris ut turpis rhoncus non rhoncus nulla feugiat. Quisque et lectus eget nisi placerat pharetra. Morbi facilisis mauris non lorem ornare nec pharetra orci mollis. In at justo et nulla pulvinar interdum. In diam odio, tincidunt ut consequat vel, vehicula quis nunc.
Praesent quis tortor lacus, ut eleifend massa. Mauris pretium, arcu a commodo iaculis, enim ligula semper enim, eu ultricies libero mi et mauris. Vestibulum imperdiet enim et elit gravida ac rhoncus tellus rhoncus. Vestibulum ac elementum mi. In venenatis magna vitae nisl imperdiet non convallis augue ultrices. Aenean nisl arcu, eleifend sed malesuada ac, varius non ante. Ut sodales nunc dolor, sit amet blandit tellus. Aliquam commodo feugiat felis sit amet tincidunt. Cras dignissim urna sit amet massa feugiat tristique. Donec orci neque, tincidunt sed aliquet malesuada, gravida et magna.
Morbi odio mauris, sollicitudin vitae ullamcorper ut, suscipit eu ipsum. Duis volutpat congue mollis. Quisque at nunc odio. Ut molestie, dolor sed feugiat pulvinar, nisl eros mattis felis, vel dignissim sapien sem eu leo. Nunc at leo arcu. Ut non ante sapien. Sed magna nunc, aliquam in elementum a, semper vel lacus. Fusce eu ultricies sapien. In ante arcu, laoreet at viverra et, tempor ut metus (PDF).
Fusce sit amet dolor massa. Maecenas urna lorem, pharetra eu molestie sit amet, tincidunt vel justo. Ut libero risus, volutpat a placerat non, egestas ut elit. In lacinia convallis tempus. In sit amet malesuada arcu. Suspendisse eget eros non nulla ornare accumsan vitae sed felis. Proin eget lectus sem. Proin porttitor fermentum dui, sit amet eleifend arcu tincidunt at. Aenean sed massa quis ligula elementum ullamcorper et at lorem. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Maecenas quis ligula est, non pretium sapien. Mauris suscipit pharetra erat nec vestibulum.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
GlaxoSmithKline Enquiries: |
|
|
|
UK Media enquiries: |
David Mawdsley |
+44 (0) 20 8047 5502 |
(London) |
|
Sarah Spencer |
+44 (0) 20 8047 5502 |
(London) |
|
David Daley |
+44 (0) 20 8047 5502 |
(London) |
|
Catherine Hartley |
+44 (0) 20 8047 5502 |
(London) |
|
Alex Harrison |
+44 (0) 20 8047 5502 |
(London) |
|
|
|
|
US Media enquiries: |
Stephen Rea |
+1 215 751 4394 |
(Philadelphia) |
|
Kevin Colgan |
+1 919 483 2933 |
(North Carolina) |
|
Melinda Stubbee |
+1 919 483 2510 |
(North Carolina) |
|
Mary Anne Rhyne |
+1 919 483 0492 |
(North Carolina) |
|
Sarah Alspach |
+1 202 715 1048 |
(Washington, DC) |
|
Jennifer Armstrong |
+1 215 751 5664 |
(Philadelphia) |
|
|
|
|
Analyst/Investor enquiries: |
Sally Ferguson |
+44 (0) 20 8047 5543 |
(London) |
|
Lucy Budd |
+44 (0) 20 8047 2248 |
(London) |
|
Tom Curry |
+ 1 215 751 5419 |
(Philadelphia) |
|
Gary Davies |
+ 44 (0) 20 8047 5503 |
(London) |
|
James Dodwell |
+ 44 (0) 20 8047 2406 |
(London) |
|
Jeff McLaughlin |
+ 1 215 751 7002 |
(Philadelphia) |
|
Ziba Shamsi |
+ 44 (0) 20 8047 3289 |
(London) |
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.


